Medication info

DONGKWANG Ibandronate Sodium Injection (Ibandronic Acid Sodium Hydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
A colorless, transparent solution in a colorless, transparent glass prefilled syringe with a single-use needle attached.
Packaging
3ml/prefilled syringe X 1
Approval status
Active

MFDS item code 201601173 · Notified 2016.02.29 · Insurance code 645906021

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as a supplement. If a dose is missed on the scheduled date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from then on. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or lower or whose creatinine clearance is 30ml/min or higher. There is insufficient clinical experience in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is below 30ml/min; therefore, use of this medicine is not recommended in these patients. Older adults No dose adjustment is necessary.
Child administration
Efficacy and safety have not been studied in children aged 18 years or younger.

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used to prevent and treat osteoporosis that may occur in postmenopausal women. It helps improve the weakening of bones due to decreased bone density after menopause and reduces the risk of fractures. Regular use can maintain bone health and is effective in preventing complications related to osteoporosis. Therefore, it is used for the treatment of osteoporosis in postmenopausal women.

How it is given

Adult administration

Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as a supplement. If a dose is missed on the scheduled date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from then on. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or lower or whose creatinine clearance is 30ml/min or higher. There is insufficient clinical experience in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is below 30ml/min; therefore, use of this medicine is not recommended in these patients. Older adults No dose adjustment is necessary.

Child administration

Efficacy and safety have not been studied in children aged 18 years or younger.

Precautions

This medication must be administered intravenously, and caution is required as tissue damage may occur if administered intra-arterially or around the vein. It should not be administered to patients with a known allergy to this drug or its ingredients, or to patients with untreated hypocalcemia. During administration, various adverse reactions such as gastrointestinal discomfort, myalgia, arthralgia, headache, fatigue, skin rash, etc., may occur, most of which are mild to moderate and often do not require cessation of treatment. In some patients, acute influenza-like symptoms, injection site reactions, or vascular inflammation may occur, and if any symptoms appear, notify the healthcare team. Serious side effects such as osteonecrosis of the jaw and external auditory canal osteonecrosis have been reported during osteoporosis treatment with this drug, so it is important for cancer patients or those requiring dental treatment to undergo oral examinations and preventive dental care before administration. If dental treatment is necessary, it should be planned with a specialist to avoid excessive procedures during treatment with this drug. This drug can temporarily lower serum calcium levels, so it is essential to correct hypocalcemia or bone/mineral metabolism disorders before administration and ensure adequate intake of calcium and vitamin D. Patients with poor kidney function or taking medications that may affect the kidneys require regular check-ups and tests. Severe bone, joint, or muscle pain may occur after administering this drug, and if such symptoms arise, consult a healthcare professional immediately. Some patients receiving this drug have reported rare occurrences of atypical femoral fractures or atypical fractures of other bones, thus evaluation should be conducted if pain occurs in the thigh or groin. The safety for pregnant or nursing women has not been established, so it is advisable not to use this drug in those populations. Toxicity may occur in the kidneys and liver in cases of overdose, so if an overdose is suspected, immediately inform healthcare professionals and receive appropriate treatment and monitoring. This drug should not be mixed with other intravenous medications or calcium-containing solutions, and must be diluted with normal saline or 5% dextrose solution for use. Do not reuse the syringe or needle after use, and dispose of them safely in a puncture-resistant container. Store out of reach of children, and the effects on driving or operating machinery are unknown, so caution is needed.

Side effects

Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reaction, phlebitis, thrombophlebitis, hypersensitivity reaction, angioedema, facial swelling, urticaria, osteonecrosis of the jaw and external auditory canal, uveitis, episcleritis, scleritis, anaphylactic reaction, shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical femoral fracture, subtrochanteric femoral fracture, muscle pain, joint pain, indigestion, influenza-like illness, musculoskeletal pain, headache, gastritis, nausea, fatigue, dizziness, fever, hypothyroidism, peripheral neuropathy, hearing loss, dyspnea, skin peeling, multiple organ failure, death, dizziness, fracture, optic nerve atrophy, lower motor neuron lesion, tremor, gastrointestinal disease, benign gastrointestinal neoplasm, toothache, hyperventilation, cough, laryngitis, vaginitis, menopausal symptoms, insomnia, anxiety, tinnitus, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, sensory loss, acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air, and the storage temperature should be maintained between 1 to 30 degrees Celsius at room temperature. Proper storage helps to maintain the drug's effectiveness.

Appearance and packaging

Appearance

A colorless, transparent solution in a colorless, transparent glass prefilled syringe with a single-use needle attached.

Package unit

3ml/prefilled syringe X 1

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.